MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...

SAN ANTONIO, November 14, 2024--bioAffinity Technologies releases financial results for the three months ended September 30, 2024.

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer ...

Biocom California, the association representing the California life science industry, today announced that it appointed Kathryn Lowell, group vice president of global government affairs at BioMarin; ...

[17] Nanotechnology-based methods of drug delivery across the BBB include two commercialized technologies LipoBridge™ (Genzyme Pharmaceuticals, MA, USA) and G-Technology® (to-BBB, Leiden ...

KH received personal compensation as a speaker for Biogen, Bristol-Myers Squibb, Roche, Teva, Novartis, Bayer, Sanofi-Genzyme and Merck. She receives currently funding by the Innovations fonds, the ...

Altimmune’s lead drug Pemvidutide demonstrates significant progress in obesity and liver health. See why ALT stock is a ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Current price $67.11 52-week high $99.56 ...